Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...

GSK has shifted towards a global marketing model influenced by a Netflix-style approach that aims to match content to the person receiving it. Richard Staines heard about this new strategy at the ...

After Pfizer's exit, UCB splits from industry trade group BIO Still, the timing of GSK’s withdrawal from the lobbying group comes just before a new U.S. president could shake things up on the ...

GSK PLC GSK shares inched up 0.20% to £15.31 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.28% to 8,282.76 ...

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by respiratory syncytial virus due to certain ...

IN MARIETTA, L Hundreds of millions of dollars and hundreds of new jobs are coming to Lancaster County.Vaccine manufacturer GSK announced Thursday it will invest $800 million to expand its ...

GSK PLC GSK shares inched down 0.03% to £14.94 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100 Index UKX falling 0.52% to 8,249.28 ...

GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager, from ...

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...

On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an investigational, oral antibiotic for adult and adolescent females with ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA editing in humans. The update on the GSK-partnered prospect sent Wave’s ...